

Nathan A. Bostick, Robert Sade, Mark A. Levine, and Dudley M. Stewart, Jr., "Placebo Use in Clinical Practice: Report of the American Medical Association Council on Ethical and Judicial Affairs," *The Journal of Clinical Ethics* 19, no. 1 (Spring 2008): 58-61.

Placebo Use in Clinical Practice: Report of the American Medical Association Council on Ethical and Judicial Affairs

*Nathan A. Bostick, Robert Sade, Mark A. Levine,
and Dudley M. Stewart, Jr.*

Nathan A. Bostick, MA, MPP, is a Senior Research Associate at the American Medical Association, Chicago, Andy.Bostick@ama-assn.org.

Robert Sade, MD, a Professor of Surgery at the Medical College of South Carolina, Charleston.

Mark A. Levine, MD, is an Associate Professor of Medicine and Preventive Medicine/Biometrics at the University of Colorado, Denver.

Dudley M. Stewart, Jr., MD, is a Clinical Professor of Psychiatry at the Louisiana State University School of Medicine in New Orleans. ©2008 by *The Journal of Clinical Ethics*. All rights reserved.

INTRODUCTION

The use of placebos in research has received much more attention than has their use in clinical practice. This report is intended to guide physicians' clinical use of placebos in ways that respect patients' autonomy by allowing them to participate actively in the medical decision-making process.

For the purposes of this report, a *placebo* is defined as a substance that the physician believes has no known specific pharmacological activity against the condition being treated. Placebos can be therapeutically beneficial to some patients when they give rise to the so-called *placebo effect*.¹ In general, this refers to a change in the patient's condition that is attributable to the symbolic aspects of the overall care, rather than the medicinal qualities of the substance prescribed by the physician.² Although there is some debate as to the origins of the placebo effect,³ much has been learned in recent years regarding its anatomical and physiological foundations.⁴

ETHICALLY APPROPRIATE PLACEBO USE

Physicians administer placebos because placebos might relieve the symptoms that cause distress to their patients.⁵ Historically, physicians used placebos without patients' knowledge, at a time when they had great latitude in providing treatment without a patient's consent if they believed the intervention to be medically indicated.⁶ Accordingly, placebos often were used to relieve pain or other complaints that appeared to have no objective medical explanation.⁷ Such use of placebos could convey benefits derived from the placebo effect or from the symbolic affirmation of physicians' willingness to help their patients.⁸

The deception associated with placebo use, however, is now widely viewed as problematic because it

directly conflicts with contemporary notions of patient autonomy and the practice of shared decision making.⁹ Today, if physicians attempt to deceive patients by representing placebos as pharmacologically active medications, they risk undermining their patients' trust.¹⁰ Loss of trust is a serious consequence because it is a foundational component of the patient-physician relationship.¹¹ If trust is undermined, patients may be less satisfied with their physicians and therefore less likely to consult them when making health-related decisions.¹² Moreover, patients may not adhere to treatment recommendations when trust in their physician has been compromised, thereby adversely affecting patients' overall health outcomes.¹³

Deceptive use of placebos poses other potential harms to patients, as well. For example, this use of placebos may mask and potentially delay the treatment of medical conditions.¹⁴ Furthermore, some patients may encounter adverse side-effects resulting from placebo use, an occurrence known as the *nocebo phenomenon*.¹⁵

Ultimately, the deceptive use of placebos is not ethically acceptable because it may harm patients to a greater degree than it helps them. This is particularly true in cases when placebos are utilized to serve the convenience of the physician rather than to promote the welfare of the patient. Perhaps the most pernicious use of placebos is for mollifying a patient who is demanding, displays a difficult personality, or has a complex problem that has become frustrating to the physician. Placebos should never be used in this way because it is fundamentally inconsistent with physicians' professional obligations to promote patients' welfare and respect the autonomy of patients.

In some instances, it may be most appropriate to forego the use of placebos altogether. Several studies have described placebo-like effects that lead to better health outcomes when physicians are able to comfort and reassure patients presenting with symptoms that do not appear to have a clear medical basis.¹⁶ This seems to work best when physicians establish partnerships with patients that are built on respect and trust, and encourage adherence to treatment plans.¹⁷

In other instances, physicians may utilize placebos within their clinical practice without relying on the act of deception. In these cases, physicians should make decisions regarding the use of placebos in partnership with their patients.¹⁸ For example, a physician could explain to a patient that a more certain diagnosis or better understanding of his or her condition could be achieved by evaluating the effects of different types of medication, including one that is not pharmacologically active, namely, a placebo.¹⁹ By obtaining the patient's cooperation in this manner, the physician need neither identify which medication is the placebo nor seek specific consent immediately before its administration.²⁰ This example of shared decision making demonstrates an approach that respects the autonomy of patients and fosters trust within the patient-physician relationship. Moreover, the authorized use of placebos is not expected to significantly diminish their clinical effectiveness as research suggests that little variation in clinical outcomes is observed between patients who are informed that they are to be treated with placebos and patients who are administered placebos in a deceptive manner.²¹

When physicians are faced with significant clinical or diagnostic uncertainty, the authorized use of placebos may prove particularly valuable for conducting single-patient controlled studies, known as *N-of-1 trials*.²² In these trials, a disease-specific intervention and a placebo are alternated through several treatment cycles; the duration of each cycle depends on the nature of the disease.²³ Such studies can be *single-blinded*, in which only the patient is unaware of which drug is being administered, or they can be *double-blinded*, in which the assignment of treatment is managed by a third person, such as a pharmacist, so neither patient nor physician knows which medication is in use. In either case, the patient keeps a detailed journal of the waxing and waning of symptoms. At the study's conclusion, the physician can differentiate between benefits attributable to the pharmacologically active drug and to the placebo.²⁴ Throughout this process, the patient's progress should be monitored and the placebo discontinued if the active agent is found clearly to be more effective.²⁵

CONCLUSION

Placebos are substances that the physician believes have no specific pharmacological activity against the condition being treated. They may be used in clinical practice to determine a diagnosis or appropriate treatment in the face of clinical uncertainty. Physicians must avoid deception when administering placebos by informing the patient that a placebo may be used.

RECOMMENDATIONS

The Council on Ethical and Judicial Affairs recommends the following.

A placebo is a substance provided to a patient that the physician believes has no specific pharmacological effect upon the condition being treated. In the clinical setting, the use of a placebo without the patient's knowledge may undermine trust, compromise the patient-physician relationship, and result in medical harm to the patient.

Physicians may use placebos for diagnosis or treatment only if the patient is informed of and agrees to its use. A placebo may still be effective if the patient knows it will be used but cannot identify it and does not know the precise timing of its use. A physician should enlist the patient's cooperation by explaining that a better understanding of the medical condition could be achieved by evaluating the effects of different medications, including the placebo. The physician need neither identify the placebo nor seek specific consent before its administration. In this way, the physician respects the patient's autonomy and fosters a trusting relationship, while the patient still may benefit from the placebo effect.

A placebo must not be given merely to mollify a difficult patient, because doing so serves the convenience of the physician more than it promotes the patient's welfare. Physicians can avoid using a placebo, yet produce a placebo-like effect through the skillful use of reassurance and encouragement. In this way, the physician builds respect and trust, promotes the patient-physician relationship, and improves health outcomes.²⁶

ACKNOWLEDGMENTS

The Council on Ethical and Judicial Affairs at the time this report was written included Robert Sade, MD (Chair); Mark A. Levine, MD (Vice-Chair); Regina Benjamin, MD, MBA; Sharon Douglas, MD; Hillary Fairbrother, MD, MPH; H. Rex Greene, MD; William Martinez, MS; John McMahon, Sr., MD, FACS, PhD; Priscilla Ray, MD; and Dudley M. Stewart, Jr., MD.

The American Medical Association Council on Ethical and Judicial Affairs gratefully acknowledges the following individuals and organizations for their efforts to review previous drafts of this report: The American Academy of Pain Medicine Council on Ethics; Paul Appelbaum, MD, the American Psychiatric Association Council on Psychiatry and Law; Perry Fine, MD, Professor of Anesthesiology, University of Utah; Richard Milone, MD, Past Chair, the American Psychiatric Association Ethics Committee; Laura Roberts, MD, Chair, the American Psychiatric Association Task Force to Update the Ethics Annotation.

NOTES

1. H. Brody, "Placebo," in *Encyclopedia of Bioethics*, ed. W.T. Reich (New York: Simon & Schuster Macmillan, 1995), 1951-3.
2. Ibid.; H. Brody, "The placebo response: Recent research and implications for family medicine," *Journal of Family Practice* 49, no. 7 (2000): 649-54.
3. A. Hróbjartsson and P.C. Gøtzsche, "An analysis of clinical trials comparing placebo with no treatment," *New England Journal of Medicine* 344 (2001): 1594-602; J. Glauziusz, "Is the placebo effect a myth?" *Discover*, 14 September 2001.

4. K. Irizarry and J. Licinio, "An explanation for the placebo effect?" *Science* 307, no. 5714 (2005): 1411-2.
5. K. Thoms, "The placebo in general practice," *Lancet* 334 (1994): 1066-7.
6. I. Kleinman, P. Brown, and L. Librach, "Placebo Pain Medication: Ethical and Practical Considerations," *Archives of Family Medicine* 3 (1994): 453-7.
7. Thoms, see note 6 above; P. Lichtenberg, U. Heresco-Levy, and U. Nitzan, "The ethics of the placebo in clinical practice," *Journal of Medical Ethics* 30 (2004): 551-4.
8. H. Spiro, "Clinical reflections on the placebo phenomenon," in *The Placebo Effect, An Interdisciplinary Exploration*, ed. A. Harrington (Cambridge: Harvard University Press, 1997), 37-55.
9. Kleinman, see note 6 above; CEJA Opinion E-10.01, "Fundamental Elements of the Patient-Physician Relationship," www.ama-assn.org/ama1/pub/upload/mm/369/ceja_6a07.pdf
10. Ibid.
11. CEJA, "Fundamental Elements of the Patient-Physician Relationship," see note 9 above.
12. T. Beauchamp and J. Childress, *Principles of Biomedical Ethics*, 5th ed. (New York: Oxford University Press, 2001).
13. D. Levy, "White doctors and black patients: influence of race on the doctor-patient relationship," *Pediatrics* 75 (1986): 639-43; A. Kao et al., "The relationship between method of physician payment and patient trust," *Journal of the American Medical Association* 280 (1998): 1708-14; D. Mechanic, "The functions and limitations of trust in the provision of medical care," *Journal of Health Politics, Policy and Law* 23 (1998): 661-86.
14. P. Hébert et al., "Bioethics for clinicians: Truth telling," *Canadian Medical Association Journal* 156 (1997): 225-8.
15. A.J. Barsky et al., "Nonspecific medication side effects and the nocebo phenomenon," *Journal of the American Medical Association* 287 (2002): 622-7.
16. Thoms, see note 5 above; K. Thomas, "General practice consultations: Is there any point in being positive?" *British Medical Journal* 294 (1987): 1200-2.
17. Brody, "The Placebo Response," see note 2 above; L. Egbert et al., "Reduction of post-operative pain by encouragement and instruction of patients," *New England Journal of Medicine* 270 (1964): 825-7.
18. CEJA Opinion E-10.01, "Fundamental Elements of the Patient-Physician Relationship," see note 9 above; CEJA Opinion E-8.08, "Informed Consent," http://www.ama-assn.org/apps/pf_new/pf_online?f_n=resultLink&doc=policyfiles/HnE/E-8.08.HTM&s_t=8.08&catg=AMA/HnE&catg=AMA/BnGnC&catg=AMA/DIR&&nth=1&&st_p=0&nth=2&
19. M. Barry, "Involving Patients in Medical Decisions: How Can Physicians Do Better?" *Journal of the American Medical Association* 282 (1999): 2356-7.
20. Beauchamp and Childress, see note 12 above, pp. 84-6.
21. M. Amanzion and F. Benedetti, "Neuropharmacological dissection of placebo analgesia: expectation activated opioid systems versus conditioning activated specific systems," *Journal of Neuroscience* 19 (1999): 484-94; L.C. Park and L. Covi, "Non-blind placebo trial: An exploration of neurotic patients' responses to placebo when its inert content is disclosed," *Archives of General Psychiatry* 12 (1965): 336-45; D. Holmes and D. Bennett, "Experiments to answer questions raised by the use of deception in psychological research: I. Role playing as an alternative to deception. II. Effectiveness of debriefing after a deception. III. Effect of informed consent on deception," *Journal of Personality and Social Psychology* 29 (1974): 358-67.
22. L. Irwig, P. Glasziou, and L. March, "Ethics of N-of-1 Trials," *Lancet* 345 (1995): 469.
23. C. Nikles, A. Clavarino, and C. Del Mar, "Using n-of-1 trials as a clinical tool to improve prescribing," *British Journal of General Practice* 55, no. 512 (2005): 175-80.
24. J.D. Price and J.G. Evance, "N-of-1 randomized controlled trials ('N-of-1 trials') singularly useful in geriatric medicine," *Age and Aging* 31 (2002): 227-32.
25. Spiro, see note 8 above.
26. Adopted by the American Medical Association House of Delegates November 2006.